Opportunities for APPs to Lead Early Alzheimer Disease Care

Panelists discuss how treatment selection must balance safety, tolerability, and evidence-based outcomes. They highlight the importance of nonpharmacologic strategies alongside medications, addressing behavioral and psychological symptoms cautiously.

Panelists discuss how new anti-amyloid therapies have shifted the treatment paradigm, requiring education and confidence among advanced practice providers (APPs) to assess appropriateness and manage potential adverse effects. The dialogue underscores the need for familiarity with clinical guidelines and trial data.

Panelists discuss how patient individuality guides therapy—factors such as comorbidities, caregiver capacity, and social context influence decisions. The holistic understanding of advanced practice providers (APPs) enables them to deliver personalized, comprehensive care.